U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Vaccines, Blood & Biologics
  3. Blood & Blood Products
  4. Approved Blood Products
  5. ATGAM
  1. Approved Blood Products

ATGAM

STN: 103676
Proper Name: lymphocyte immune globulin,anti-thymocyte globulin[equine])
Tradename: ATGAM
Manufacturer: Pharmacia & Upjohn Company LLC, a Pfizer company
Indications:

  • Renal transplant rejection.
  • Aplastic anemia (moderate to severe) in patients unsuitable for bone marrow transplantation.
  • Limitations of Use:
    The usefulness of ATGAM has not been demonstrated in patients with aplastic anemia who are suitable candidates for bone marrow transplantation or in patients with aplastic anemia secondary to neoplastic disease, storage disease, myelofibrosis, Fanconi’s syndrome, or in patients known to have been exposed to myelotoxic agents or radiation.

Product Information

Supporting Documents

 

Back to Top